CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

1.68
-0.05  -3%
Previous Close 1.73
Open 1.75
Price To book 7.00
Market Cap 27476316
Shares 16,354,950
Volume 26,542
Short Ratio 4.37
Av. Daily Volume 31,881

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 failed to meet endpoint - July 2016
CF101
Glaucoma
Phase 2 completion of enrollment announced August 9, 2017.
Namodenoson (CF102)
Cancer - advanced liver cancer second line
Phase 3 enrollment to commence 3Q 2017.
CF101
Rheumatoid arthritis
Phase 2/3 trial did not meet primary endpoint late March 2015. Additional Phase 3 planned, with trial protocol to be submitted 4Q 2017.
CF101
Psoriasis
Phase 2 enrollment to be completed 3Q 2017.
CF102
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Can-Fite Files Patent Application to Treat Cytokine Release Syndrome, a Potentially Life-Threatening Complication of CAR-T Cell Therapy
  2. Can-Fite Reports Second Quarter 2017 Financial Results & Provides Clinical Update
  3. Featured Company News – Can-Fite Receives Second Milestone Payment From CKD Pharmaceuticals for Namodenoson (CF102) in South Korea
  4. Can-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution Partner in Korea
  5. Can-Fite Completes Patient Enrolment for its Phase II Study of Namodenoson in the Treatment of Liver Cancer
  6. Can-Fite Successfully Completes Human Cardiodynamic Safety Trial for Piclidenoson
  7. Can-Fite’s Phase II NAFLD/NASH Trial with Namodenoson Set to Commence Patient Enrollment Following Conclusion of Successful Clinical Investigator Meeting
  8. Can-Fite to Participate in Bio International Convention in San Diego on June 19-22, 2017
  9. Can-Fite Concludes Successful Clinical Investigator Meeting for its ACRobat Phase III Trial of Piclidenoson in the Treatment of Rheumatoid Arthritis
  10. Can-Fite Establishes Clinical Advisory Board for NAFLD/NASH
  11. New Preclinical Data on Can-Fite's Namodenoson to be Presented at 1st International Conference on Fatty Liver in Seville, Spain on June 2, 2017
  12. Can-Fite Reports First Quarter 2017 Financial Results & Provides Clinical Update
  13. Can-Fite Files Clinical Trial Application in Canada for Piclidenoson Ahead of Upcoming Acrobat Rheumatoid Arthritis Phase III Study
  14. Can-Fite's Liver Protective Drug Namodenoson Enters Phase II Trial for Treatment of NAFLD/NASH
  15. Can-Fite's Phase III ACRobat Trial in Rheumatoid Arthritis Approved by Institutional Review Board
  16. Can-Fite Reports 2016 Financial Results & Provides Clinical Update
  17. New Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis
  18. CANF: Ready to Start Two Phase III Trials in 2017
  19. Can-Fite Gears Up for ACRobat, its Phase III Trial of Piclidenoson in Rheumatoid Arthritis
  20. Can-Fite BioPharma Announces $5 Million Registered Direct Offering